Vera Therapeutics Inc
VERA
$39.65
Closing
▼-3.15%
1D
▲151.56%
YTD
Market cap
$2.16B
52 week high
$50.69
52 week low
$6.10
Volume
279,428
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$2.16B
Analysts' Rating
BUY
Price Target (Mean)
22.85714
Total Analysts
7
P/E
Operating Margin
0.00%
Beta
Revenue Growth (Annual)
0.00%
52 week high
$50.69
52 week low
$6.10
Div. Yield
%
EPS Annual Growth
-2.17
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Atacicept is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease, and early death. The Company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants.
